Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally.
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Achieve Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SP4N's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: SP4N underperformed the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: SP4N underperformed the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is Achieve Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Achieve Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SP4N's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SP4N's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SP4N is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SP4N is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SP4N's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SP4N is good value based on its PB Ratio (0.5x) compared to the DE Biotechs industry average (3.5x).
How is Achieve Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SP4N is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: SP4N is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SP4N's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if SP4N's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if SP4N's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SP4N's Return on Equity is forecast to be high in 3 years time
How has Achieve Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SP4N is currently unprofitable.
Growing Profit Margin: SP4N is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SP4N is unprofitable, and losses have increased over the past 5 years at a rate of -48.8% per year.
Accelerating Growth: Unable to compare SP4N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SP4N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: SP4N has a negative Return on Equity (-206.83%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Achieve Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: SP4N's short term assets ($7.6M) exceed its short term liabilities ($3.1M).
Long Term Liabilities: SP4N's short term assets ($7.6M) exceed its long term liabilities ($212.0K).
Debt to Equity History and Analysis
Debt Level: SP4N is debt free.
Reducing Debt: SP4N had no debt 5 years ago.
Inventory Level: SP4N has a low level of unsold assets or inventory.
Debt Coverage by Assets: SP4N's debt is not covered by short term assets (assets are -18.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SP4N has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SP4N has less than a year of cash runway if free cash flow continues to reduce at historical rates of -54.8% each year
What is Achieve Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate SP4N's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SP4N's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SP4N's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SP4N's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SP4N's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Stewart (60yo)
Dr. Richard A. B. Stewart, also known as Rick, has been Chairman, Chief Executive Officer and Director of Achieve Life Sciences, Inc. since August 2017. Dr. Stewart has been a Founder of Ricanto Limited, a ...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD1.09M) is above average for companies of similar size in the German market ($USD412.37K).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
|Chairman of the Board & CEO||2.5yrs||US$1.09m||1.05% $107.3k|
|Executive VP||5.5yrs||US$694.71k||0.010% $1.0k|
|Executive VP & Chief Medical Officer||11.5yrs||US$712.21k||0.013% $1.4k|
|Executive Vice President of Commercial||3.1yrs||no data||no data|
Experienced Management: SP4N's management team is considered experienced (3.1 years average tenure).
|Chairman of the Board & CEO||2.5yrs||US$1.09m||1.05% $107.3k|
|Non-Employee Director||9.9yrs||US$82.15k||0.00056% $57.2|
|Non-Employee Director||2.5yrs||US$80.65k||no data|
|Non-Employee Director||11.5yrs||US$62.15k||0.012% $1.2k|
|Lead Independent Director||0yrs||US$98.15k||no data|
|Non-Employee Director||9.7yrs||US$83.15k||0.00045% $46.0|
Experienced Board: SP4N's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 236.5%.
Achieve Life Sciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Achieve Life Sciences, Inc.
- Ticker: SP4N
- Exchange: DB
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$11.074m
- Listing Market Cap: US$10.221m
- Shares outstanding: 20.93m
- Website: https://www.achievelifesciences.com
Number of Employees
- Achieve Life Sciences, Inc.
- 1040 West Georgia Street
- Suite 1030
- British Columbia
- V6E 4H1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ACHV||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Aug 2017|
|SP4N||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2017|
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol; and a strategic collaboration with National Institutes of Health for the development of cytisinicline for smoking cessation. The company is based in Vancouver, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 22:44|
|End of Day Share Price||2020/02/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.